Loading...
•
Dec 31, 2023
Y-mAbs Q4 2023 Earnings Report
Y-mAbs reported increased DANYELZA net product revenues and reduced research and development expenses.
Key Takeaways
Y-mAbs reported a net loss of $1.0 million for Q4 2023, with DANYELZA net product revenues reaching $23.4 million, a 42% increase compared to the same period in 2022. The company's cash and cash equivalents were approximately $78.6 million as of December 31, 2023, expected to support operations into 2027.
DANYELZA net product revenues were $23.4 million, a 42% increase year-over-year.
Research and development expenses decreased by 32% compared to the same quarter in the previous year.
Net loss for the quarter was $1.0 million, compared to net income of $1.2 million in Q4 2022, which included $15.0 million of license revenue.
Cash and cash equivalents totaled $78.6 million as of December 31, 2023.
Revenue by Geographic Location
Forward Guidance
Y-mAbs expects its cash and cash equivalents, together with anticipated DANYELZA product revenues, to support operations as currently planned into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...